Antibodies against RAGE in sepsis and inflammation: implications for therapy

Bibliography

• ZIEGLER EJ, FISHER CJ Jr, SPRUNG CL et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. (1991) 324:429-436.
   PubMed Web of Science ®Google Scholar
• GREENMAN RL, SCHEIN RM, MARTIN MA et al.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 266:1097-1102.
   PubMed Web of Science ®Google Scholar
• WILLATTS SM, RADFORD S, LEITERMANN M: Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: A placebo-controlled, double-blind trial. Crit. Care Med. (1995) 23:1033-1039.
   PubMed Web of Science ®Google Scholar
• FISHER CJ Jr, SLOTMAN GJ, OPAL SM et al.: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. (1994) 22:12-21.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JF, TENAILLON A, LE TULZO Y et al.: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit. Care Med. (1994) 22:1720-1728.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, SPAPEN H, BAKKER J et al.: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. (2000) 28:638-642.
   PubMed Web of Science ®Google Scholar
• FISHER CJ Jr, AGOSTI JM, OPAL SM et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N. Engl. J. Med. (1996) 334:1697-1702.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, GLAUSER MP, BUTLER T et al.: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA (1997) 277:1531-1538.
   PubMed Web of Science ®Google Scholar
• FEIN AM, BERNARD GR, CRINER GJ et al.: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA (1997) 277:482-487.
   PubMed Web of Science ®Google Scholar
• WARREN BL, EID A, SINGER P et al.: High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA (2001) 286:1869-1878.
   PubMed Web of Science ®Google Scholar
• WIEDERMANN CJ, HOFFMANN JN, JUERS M et al.: High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit. Care Med. (2006) 34:285-292.
   PubMed Web of Science ®Google Scholar
• OPAL S, LATERRE PF, ABRAHAM E et al.: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. (2004) 32:332-341.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JF, LATERRE PF, JANES JM et al.: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. (2003) 29:894-903.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, BERNARD GR, BEALE R et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med. (2005) 33:2266-2277.
   PubMed Web of Science ®Google Scholar
• OPAL SM: Can we resolve the treatment of sepsis? Lancet (2007) 369:803-804.
   PubMed Web of Science ®Google Scholar
• NEEPER M, SCHMIDT AM, BRETT J et al.: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. (1992) 267:14998-15004.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AM, VIANNA M, GERLACH MJ et al.: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. (1992) 267:14987-14997.
   PubMed Web of Science ®Google Scholar
• HORI O, BRETT J, SLATTERY T et al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J. Biol. Chem. (1995) 270:25752-25761.
   PubMed Web of Science ®Google Scholar
• HOFMANN MA, DRURY S, FU C et al.: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 97:889-901.
   PubMed Web of Science ®Google Scholar
• CHAVAKIS T, BIERHAUS A, AL-FAKHRI N et al.: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. (2003) 198:1507-1515.
   PubMed Web of Science ®Google Scholar
• LI J, SCHMIDT AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. (1997) 272:16498-16506.
   PubMed Web of Science ®Google Scholar
• FLYVBJERG A, DENNER L, SCHRIJVERS BF et al.: Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes (2004) 53:166-172.
   PubMed Web of Science ®Google Scholar
• JENSEN LJN, DENNER L, SCHRIJVERS BF, TILTON RG, RASCH R, FLYVBJERG A: Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. (2006) 188:493-501.
   PubMed Web of Science ®Google Scholar
• KOKA V, WANG W, HUANG XR, KIM-MITSUYAMA S, TRUONG LD, LAN HY: Advanced glycation end products activate a chymase-dependent angiotensin II generating pathway in diabetic complications. Circulation (2006) 113:1353-1360.
   PubMed Web of Science ®Google Scholar
• HOFMANN MA, DRURY S, HUDSON BI et al.: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. (2002) 3:123-135.
   PubMed Web of Science ®Google Scholar
• BASTA G, LAZZERINI G, MASSARO M et al.: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE. A mechanism for amplification of inflammatory responses. Circulation (2002) 105:816-822.
   PubMed Web of Science ®Google Scholar
• CECIL DL, JOHNSON K, REDISKE J, LOTZ M, SCHMIDT AM, TERKELTAUB R: Inflammation-induced chrondrocyte hypertrophy is driven by receptor for advanced glycation end products. J. Immunol. (2005) 175:8296-8302.
   PubMed Web of Science ®Google Scholar
• LALLA E, LAMSTER IB, FEIT Met al.: Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J. Clin. Invest. (2000) 105:1117-1124.
   PubMed Web of Science ®Google Scholar
• MOSER B, SZABOLCS MS, ANKERSMIT JH et al.: Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am. J. Transplant. (2007) 7:293-302.
   PubMed Web of Science ®Google Scholar
• ZEN K, CHEN CXJ, CHEN YT, WILTON R, LIU Y: Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J. of Immunol. (2007) 178:2483-2490.
   PubMed Web of Science ®Google Scholar
• PARK JS, SVETKAUSKAITE D, HE Q et al.: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. (2004) 279:7370-7377.
   PubMed Web of Science ®Google Scholar
• YANG H, OCHANI M, LI J et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA (2004) 101:296-301.
   PubMed Web of Science ®Google Scholar
• WANG H, BLOOM O, ZHANG M et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 285:248-251.
   PubMed Web of Science ®Google Scholar
• TREUTIGER CJ, MULLINS GE, JOHANSSON AS et al.: High mobility group 1 B-box mediates activation of human endothelium. J. Intern. Med. (2003) 254:375-385.
   PubMed Web of Science ®Google Scholar
• REDDY MA, LI SL, SAHAR S et al.: Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem. (2006) 281:13685-13693.
   PubMed Web of Science ®Google Scholar
• LILIENSIEK B, WEIGAND MA, BIERHAUS A et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. (2004) 113:1641-1650.
   PubMed Web of Science ®Google Scholar
• LUTTERLOH EC, OPAL SM, KEITH JC et al.: Administration of antibody against the receptor for advanced glycation end products (RAGE) improves survival in a murine model of polymicrobial sepsis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 – 30 September 2006) B-668.
   Google Scholar
• CLERMONT G, BARTELS J, KUMAR T, CONSTANTINE G, VODOVOTZ Y, CHOW C: In silico design of clinical trials: a method coming of age. Crit. Care Med. (2004) 32:2061-2070.
   PubMed Web of Science ®Google Scholar
• KUMAR R, CLERMONT G, VODOVOTZ Y, CHOW CC: The dynamics of acute inflammation. J. Theor. Biol. (2004) 230:145-155.
   PubMed Web of Science ®Google Scholar
• VODOVOTZ Y, CHOW CC, BARTELS J et al.: In silico models of acute inflammation in animals. Shock (2006) 26:235-244.
   PubMed Web of Science ®Google Scholar
• CROSS AS, OPAL SM: A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann. Intern. Med. (2003) 138:502-505.
   PubMed Web of Science ®Google Scholar